At the time of the survey, only 9% of patients with stage III melanoma were treated with targeted therapy (BRAF/MEK inhibitors); 91% were receiving immune checkpoint inhibitors (ICIs; e.g., programed cell death protein‐1 [PD‐1] inhibitors; note, immune therapy is not mutually exclusive to targeted therapy). Here, MAP2K7 is linked to melanoma.